Invariant natural killer T cells: bridging innate and adaptive immunity

被引:0
|
作者
Luc Van Kaer
Vrajesh V. Parekh
Lan Wu
机构
[1] Vanderbilt University School of Medicine,Department of Microbiology and Immunology
来源
Cell and Tissue Research | 2011年 / 343卷
关键词
CD1d; Glycolipids; Immunomodulation; Innate immunity; Invariant natural killer T cells;
D O I
暂无
中图分类号
学科分类号
摘要
Cells of the innate immune system interact with pathogens via conserved pattern-recognition receptors, whereas cells of the adaptive immune system recognize pathogens through diverse, antigen-specific receptors that are generated by somatic DNA rearrangement. Invariant natural killer T (iNKT) cells are a subset of lymphocytes that bridge the innate and adaptive immune systems. Although iNKT cells express T cell receptors that are generated by somatic DNA rearrangement, these receptors are semi-invariant and interact with a limited set of lipid and glycolipid antigens, thus resembling the pattern-recognition receptors of the innate immune system. Functionally, iNKT cells most closely resemble cells of the innate immune system, as they rapidly elicit their effector functions following activation, and fail to develop immunological memory. iNKT cells can become activated in response to a variety of stimuli and participate in the regulation of various immune responses. Activated iNKT cells produce several cytokines with the capacity to jump-start and modulate an adaptive immune response. A variety of glycolipid antigens that can differentially elicit distinct effector functions in iNKT cells have been identified. These reagents have been employed to test the hypothesis that iNKT cells can be harnessed for therapeutic purposes in human diseases. Here, we review the innate-like properties and functions of iNKT cells and discuss their interactions with other cell types of the immune system.
引用
收藏
页码:43 / 55
页数:12
相关论文
共 50 条
  • [11] Natural Killer Cells: From Innate to Adaptive Features
    Mujal, Adriana M.
    Delconte, Rebecca B.
    Sun, Joseph C.
    ANNUAL REVIEW OF IMMUNOLOGY, VOL 39, 2021, 39 : 417 - 447
  • [12] Invariant natural killer T cells as sensors and managers of inflammation
    Van Kaer, Luc
    Parekh, Vrajesh V.
    Wu, Lan
    TRENDS IN IMMUNOLOGY, 2013, 34 (02) : 50 - 58
  • [13] Antitumor Immunity Exerted by Natural Killer and Natural Killer T Cells in the Liver
    Nakashima, Hiroyuki
    Kinoshita, Manabu
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [14] The in vivo response of invariant natural killer T cells to glycolipid antigens
    Parekh, Vrajesh V.
    Lalani, Saif
    Van Kaer, Luc
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2007, 26 (1-2) : 31 - 48
  • [15] Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis
    Bianchini, Elena
    De Biasi, Sara
    Simone, Anna Maria
    Ferraro, Diana
    Sola, Patrizia
    Cossarizza, Andrea
    Pinti, Marcello
    IMMUNOLOGY LETTERS, 2017, 183 : 1 - 7
  • [16] Natural interferon α/β-producing cells link innate and adaptive immunity
    Kadowaki, N
    Antonenko, S
    Lau, JYN
    Liu, YJ
    JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (02) : 219 - 225
  • [17] Reciprocal Interactions Between Human Mesenchymal Stem Cells and γδ T Cells Or Invariant Natural Killer T Cells
    Prigione, Ignazia
    Benvenuto, Federica
    Bocca, Paola
    Battistini, Luca
    Uccelli, Antonio
    Pistoia, Vito
    STEM CELLS, 2009, 27 (03) : 693 - 702
  • [18] Activation and Regulation of B Cell Responses by invariant Natural Killer T Cells
    Doherty, Derek G.
    Melo, Ashanty M.
    Moreno-Olivera, Ana
    Solomos, Andreas C.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [19] Activation mechanisms of invariant natural killer T cells (iNKTs)
    Baena, Andres
    Gomez-Giraldo, Lina
    Carreno, Leandro J.
    IATREIA, 2016, 29 (01) : 51 - 64
  • [20] Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity
    Sanchez, C. J.
    Le Treut, T.
    Boehrer, A.
    Knoblauch, B.
    Imbert, J.
    Olive, D.
    Costello, R. T.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (01) : 1 - 13